Objective To explore the curative effect of programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors combined with platinum chemotherapy on advanced triple-negative breast cancer (TNBC) and the influences on 3-year survival rate.Methods A retrospective collection was performed on case data of 90 patients with advanced TNBC admitted to the hospital from April 2016 to August 2019. According to the final treatment methods, they were divided into observation group (n=47) and control group (n=43)The control group was given gemcitabine, cisplatin chemotherapy and routine treatment, while observation group was additionally given Pembrolizumab injection. The levels of serum tumor markers before and after treatment, clinical curative effect, incidence of adverse reactions and 3-year survival rate after treatment were compared between the two groups. Results Before treatment, there was no significant difference between the two groups in levels of tumor markers (P＞0.05) After treatment, levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and carbohydrate antigen 125 (CA125) in observation group were significantly lower than those in control group (P＜0.05), objective remission rate (ORR) and disease control rate (DCR) were significantly higher than those in control group (P＜0.05) There was no significant difference in the incidence of adverse reactions or 3-year survival rate between the two groups (P＞0.05) Conclusion PD-1/PD-L1 inhibitors combined with platinum chemotherapy can effectively improve curative effect and levels of serum tumor markers in advanced TNBC, with high safety. And it provides certain reference for the clinical usage of PD-1/PD-L1 inhibitors in the treatment of advanced TNBC